Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells

Experimental and Molecular Medicine

Volumn 48, Issue 8, 2016, Pages

  Kim, Dae Kyoung ^a   Seo, Eun Jin ^a   Choi, Eun J ^a   Lee, Su In ^a   Kwon, Yang Woo ^a   Jang, Il Ho ^a   Kim, Seung Chul ^a   Kim, Ki Hyung ^a   Suh, Dong Soo ^a   Seong Jang, Kim ^a   Lee, Sang Chul ^b   Kim, Jae Ho ^a,c  

^a Pusan National University School of Medicine   (South Korea)

^b Epigenomics Research Center of Genome Institute   (South Korea)

^c Yangsan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; KRUPPEL LIKE FACTOR 4; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HIGH MOBILITY GROUP A1A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER STEM CELL; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPHEROID CELL; STEM CELL SELF-RENEWAL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; OVARY; OVARY TUMOR; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA1A PROTEIN; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; OVARY; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84985990238     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2016.73     Document Type: Article

References (50)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
4. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
5. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
7. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
8. Burleson KM, Boente MP, Pambuccian SE, Skubitz AP. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med 2006; 4: 6.
9. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007; 46: 872-885.
10. L'Esperance S, Bachvarova M, Tetu B, Mes-Masson AM, Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008; 9: 99.
11. Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 2007; 6: 11.
12. Mosca E, Cocola C, Sabour D, Pelucchi P, Bertalot G, Palumbo O et al. Overlapping genes may control reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs) and breast cancer stem cells. In Silico Biol 2010; 10: 207-221.
13. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
14. Shah SN, Kerr C, Cope L, Zambidis E, Liu C, Hillion J et al. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS ONE 2012; 7: E48533.
15. Reeves R. Nuclear functions of the HMG proteins. Biochim Biophys Acta 2010; 1799: 3-14.
16. Sgarra R, Zammitti S, Lo Sardo A, Maurizio E, Arnoldo L, Pegoraro S et al. HMGA molecular network: From transcriptional regulation to chromatin remodeling. Biochim Biophys Acta 2010; 1799: 37-47.
17. Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004; 574: 1-8.
18. Shah SN, Resar LM. High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol 2012; 27: 567-579.
19. Battista S, Pentimalli F, Baldassarre G, Fedele M, Fidanza V, Croce CM et al. Loss of Hmga1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J 2003; 17: 1496-1498.
20. Belton A, Gabrovsky A, Bae YK, Reeves R, Iacobuzio-Donahue C, Huso DL et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS ONE 2012; 7: E30034.
21. Schuldenfrei A, Belton A, Kowalski J, Talbot CC Jr, Di Cello F, Poh W et al. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics 2011; 12: 549.
22. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget 2013; 4: 1293-1308.
23. Shah SN, Cope L, Poh W, Belton A, Roy S, Talbot CC Jr et al. HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells. PLoS ONE 2013; 8: E63419.
24. Puca F, Colamaio M, Federico A, Gemei M, Tosti N, Bastos AU et al. HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p53 levels. Oncotarget 2014; 5: 3234-3245.
25. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933-2942.
26. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001; 1520: 234-241.
27. Zhou N, Wu X, Yang B, Yang X, Zhang D, Qing G. Stem cell characteristics of dormant cells and cisplatininduced effects on the stemness of epithelial ovarian cancer cells. Mol Med Rep 2014; 10: 2495-2504.
28. Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H et al. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol 2015; 137: 299-305.
29. Huso TH, Resar LM. The high mobility group A1 molecular switch: Turning on cancer - can we turn it off? Expert Opin Ther Targets 2014; 18: 541-553.
30. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M et al. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003; 278: 14146-14152.
31. Seo EJ, Kwon YW, Jang IH, Kim DK, Lee SI, Choi EJ et al. Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism. Stem Cells 2016; 34: 551-564.
32. Choi EJ, Seo EJ, Kim DK, Lee SI, Kwon YW, Jang IH et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget 2016; 7: 3506-3519.
33. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000; 60: 4256-4261.
34. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE et al. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000; 20: 5490-5502.
35. Liu Y, Wang Y, Zhang Y, Fu J, Zhang G. Knockdown of HMGA1 expression by short/small hairpin RNA inhibits growth of ovarian carcinoma cells. Biotechnol Appl Biochem 2012; 59: 1-5.
36. Yanagisawa BL, Resar LM. Hitting the bull's eye: Targeting HMGA1 in cancer stem cells. Expert Rev Anticancer Ther 2014; 14: 23-30.
37. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: The aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008; 4: 697-720.
38. Pors K, Moreb JS. Aldehyde dehydrogenases in cancer: An opportunity for biomarker and drug development? Drug Discov Today 2014; 19: 1953-1963.
39. Xu X, Chai S, Wang P, Zhang C, Yang Y, Yang Y et al. Aldehyde dehydrogenases and cancer stem cells. Cancer Lett 2015; 369: 50-57.
40. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010; 70: 5163-5173.
41. Shao C, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez-Canales J et al. Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway. Clin Cancer Res 2014; 20: 4154-4166.
42. Liu SY, Zheng PS. High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer. Oncotarget 2013; 4: 2462-2475.
43. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 327-337.
44. Meng E, Mitra A, Tripathi K, Finan MA, Scalici J, McClellan S et al. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. PLoS ONE 2014; 9: E107142.
45. Yasuda K, Torigoe T, Morita R, Kuroda T, Takahashi A, Matsuzaki J et al. Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. PLoS ONE 2013; 8: E68187.
46. Pallante P, Sepe R, Puca F, Fusco A. High mobility group a proteins as tumor markers. Front Med 2015; 2: 15.
47. Liau SS, Ashley SW, Whang EE. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J Gastrointest Surg 2006; 10: 1254-1262.
48. Liau SS, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008; 14: 1470-1477.
49. D'Angelo D, Mussnich P, Rosa R, Bianco R, Tortora G, Fusco A. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer 2014; 14: 851.
50. Reeves R, Wolffe AP. Substrate structure influences binding of the non-histone protein HMG-I(Y) to free nucleosomal DNA. Biochemistry 1996; 35: 5063-5074.